The Zhitong Finance App learned that Junshi Biotech (01877) fell by more than 3%. As of press release, it fell 3.21% to HK$15.37, with a turnover of HK$25.338 million.

According to the news, on October 29, Junshi Biotech announced that for the first three quarters of 2026, revenue was 2,513 billion yuan, up 39.18% year on year; net loss attributable to shareholders of listed companies was 149 million yuan, a year-on-year narrowing 75% year on year; basic loss per share was 0.15 yuan.

In addition, Junshi Biotech announced that recently, the company's product recombinant humanized anti-PD-1 and VEGF bispecific antibody (code: JS207) combined with the recombinant humanized anti-CTLA4 monoclonal antibody (code: JS007) has completed a multi-center, randomized, controlled, open phase III clinical study on the efficacy and safety of bitriplimab combined with bevacizumab in first-line treatment of advanced hepatocellular carcinoma (hereinafter referred to as “JS207-017-III-HCC study”, NCT07823348). This study is the first domestically registered clinical study of JS207.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.